Functional Haplotypes of the hTERT Gene, Leukocyte Telomere Length Shortening, and the Risk of Peripheral Arterial Disease by Zhang, Weili et al.
 
Functional Haplotypes of the hTERT Gene, Leukocyte Telomere
Length Shortening, and the Risk of Peripheral Arterial Disease
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zhang, Weili, Yu Chen, Xiaomin Yang, Jingyao Fan, Xuenan Mi,
Jizheng Wang, Channa Zhang, Frank B. Hu, and Rutai Hui. 2012.
Functional haplotypes of the hTERT gene, leukocyte telomere
length shortening, and the risk of peripheral arterial disease. PLoS
ONE 7(10): e47029.
Published Version doi:10.1371/journal.pone.0047029
Accessed February 19, 2015 11:49:59 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579675
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAFunctional Haplotypes of the hTERT Gene, Leukocyte
Telomere Length Shortening, and the Risk of Peripheral
Arterial Disease
Weili Zhang
1*, Yu Chen
1, Xiaomin Yang
2, Jingyao Fan
1, Xuenan Mi
1, Jizheng Wang
1, Channa Zhang
1,
Frank B. Hu
3, Rutai Hui
1
1Sino-German Laboratory for Molecular Medicine, the State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese
Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2The Second Affiliated Hospital of Baotou Medical College, Baotou City, China,
3Department of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
Abstract
Background: The development of peripheral arterial disease (PAD) is heterogeneous even in the presence of similar risk
factors. Our aim was to determine whether inter-individual differences in leukocyte telomere length contribute to the
susceptibility of PAD.
Methods: A total of 485 patients with PAD (defined by the ankle-brachial index) and 970 age- and gender-matched controls
were recruited from seven rural communities in Henan Province in China. The relative leukocyte telomere length was
determined by a quantitative PCR-based method. Two common promoter variants of the hTERT gene were genotyped to
assess their effects on telomere length and the risk of PAD. In vivo luciferase assay was performed to study the
transcriptional activity.
Results: After adjustment for vascular risk factors and genetic variants in the hTERT gene, individuals in the lowest and
middle tertiles of telomere length had a significantly higher risk of PAD than did those in the highest tertile (odds ratio [OR]
1.73, 95% confidence interval [CI] 1.29–2.49 in the middle tertile; 3.15, 95%CI 2.31–4.29 in the lowest tertile). Haplotype
analysis using the 2 variants (rs2735940 and rs2853669) showed that subjects with the at-risk C-C haplotype had shorter
telomere length than those individuals with the T-T haplotype and consistently had 1.30-fold (OR 1.30, 95%CI 1.06–1.58;
P=0.005) increased risk for PAD. The C-C haplotype had 43% lowered transcription activity of hTERT promoter (P,0.001).
Conclusion: The associations between the functional haplotype of hTERT gene and telomere length and the risk of
atherosclerotic PAD suggested that mean leukocyte telomere length may independently serve as a potential predictor of
PAD.
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Introduction
Atherosclerotic peripheral arterial disease (PAD) is a disease
characterized by progressive narrowing of arteries in the lower
limbs, and patients often suffer from leg ischemia, intermittent
claudication, and reduced quality of life. Importantly, both
asymptomatic and symptomatic PAD are associated with in-
creased risk of stroke, myocardial infarction, and death [1–4].
PAD affects approximately 8–10 million people in the United
States [5] and is increasingly prevalent in Europe and Asia [6–8].
In China, the prevalence of PAD was 8.7% among hypertensive
patients in our previous study [9]. PAD patients have vascular risk
factors similar to that of coronary artery disease, whereas at an
individual level, the progression of PAD seems to be highly
variable even in the presence of the similar risk factors profiles.
The inter-individual heterogeneities are still incompletely under-
stood, but biological aging is one of the contributors.
Telomere attrition represents one molecular mechanism that
contributes to cellular aging. Telomeres are specialized DNA-
protein structures at the end of all chromosomes, which preserve
chromosome stability and integrity [10]. During somatic cell
division, DNA polymerase cannot fully replicate the 39 end of
linear DNA, resulting in a progressive loss of telomeres. When
telomere lengths are shortened to a critical value, they lose capping
function at the chromosomal ends, activate the DNA damage
checkpoints, and eventually result in cellular senescence/apoptosis
which has been linked with the pathogenesis of atherosclerosis
[11]. Synthesis and maintenance of telomeres are mediated by a
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Human telomerase catalytic subunit, encoded by telomerase
reverse transcriptase (hTERT) gene, has shown to be a rate-
limiting determinant of telomerase activity and maintains genomic
stability by adding the telomere repeat TTAGGG to telomere
ends [12–14]. Recent experimental studies suggested a protective
effect of hTERT against endothelial dysfunction [11,15,16].
Leukocyte telomere length is inheritable and there is consider-
able inter-individual variation among people of the similar age
[17]. Its heritability has been estimated to be between 35% and
80% on the basis of twin and family studies [18–20]. A number of
suggestive genetic loci for telomere length in humans have been
mapped to chromosome 3p26.1, 10q26.13, 12q12.22, 14q23.2 in
family-based linkage studies [19–21] and to chromosome 18q12.2
[22], 3q26 [23,24,25], 10q24.33 [25], and 14q21 [26] in recent
genome-wide association analyses; but these identified loci, except
for TERC gene, are not replicated in multiple independent studies
and only explain a small fraction of the heritability of telomere
length. And none of the identified variants have been associated
with cardiovascular disease [27]. In contrast, functional variants in
hTERT gene have been reported to be associated with telomere
length and the risk of coronary heart disease in some studies
although not in others [28–30].
Emerging studies have provided consistent evidence that
telomere length shortening is a potential risk predictor for
coronary heart disease [31,32]; however, despite the prevalence
and high societal burden of PAD, our understanding of the genetic
basis of PAD is still limited [33,34]. Therefore, in the current
community-based case-control study, we aimed to investigate
whether mean leukocyte telomere length is a predictor of the
development of atherosclerotic PAD, and evaluate the effect of
common variants in the hTERT gene on risk difference of PAD.
Methods
Ethics Statement
The study was complied with the Declaration of Helsinki and
was approved by Institutional Review Board and Ethics Commit-
tee of Fu Wai Hospital. All participants reported themselves as
Han nationality, and provided written informed consent.
Study Population
This community-based case-control study consisted of 485
patients with PAD and 970 control subjects who were from seven
rural communities at the XinYang Country in the middle region
in China from 2004 to 2005 [9]. PAD was diagnosed when
patients had typical symptoms of intermittent claudication, such as
cramping pain of the calves or buttocks during exercise, or an
ankle-brachial index (ABI) of #0.9 in either leg, calculated
according to the recommendations of the American Heart
Association [35]. The ABI was determined from Doppler-derived
measurements of systolic blood pressure at the brachial and ankle
arteries (detailed description shown in the File S1). An ABI .0.9
and #1.4 in both legs was considered normal. Subjects were
excluded when they had any known diseases including heart
failure, valvular heart disease, secondary hypertension, and severe
debilitating chronic illness (cancer, renal, or hepatic diseases). For
each case, 2 control subjects matched by age (65 years) and
gender and without PAD were recruited from the same
communities.
Each participant was interviewed in a community clinic and
completed a standardized questionnaire that included demograph-
ic factors, medical history, lifestyle, and familial history. Anthro-
pometric measurements, including height, weight, waist and hip
circumference (measured at the umbilicus and the widest point,
respectively), were measured by trained researchers. Electrocar-
diogram was performed in all participants. Hypertension was
defined as systolic blood pressure of $140 mmHg or diastolic
blood pressure of $90 mmHg or currently taking medication for
hypertension.
Fasting blood was drawn from an antecubital vein after
overnight. Serum was separated on-site, then transported on dry
ice to Beijing center laboratory, and stored at 270uC until
measurement. Biochemical variables, including blood glucose,
total cholesterol, triglycerides, high-density lipoprotein (HDL)
cholesterol, and uric acid were assayed by an automatic analyzer
(Hitachi 7060, Tokyo, Japan) in the core laboratory at FuWai
Hospital.
Leukocyte Telomere Length Assay
Genomic DNA was isolated from peripheral blood leukocytes
according to standard procedures. Relative mean leukocyte
telomere length was determined with a quantitative real-time
polymerase chain reaction (PCR)-based technique that compares
telomere repeat copy number (T) to single-copy gene copy number
(S) (T/S ratio) in a given sample [36]. All PCRs were performed
on the Bio-Rad DNA Engine Opticon 2 Real-time PCR Detector
(Bio-Rad Ltd, Hercules, CA, USA).
In brief, two master mixes of PCR reagents were prepared, one
for the telomere reaction and one for the single-copy gene reaction
(b-globin gene on chromosome 11p15.5). The primer sequences
and thermal cycling profiles were given in details in the File S1. All
samples for both the telomere and single-copy gene amplifications
were done in duplicate in 96-well plates. The human embryonic
kidney 293 (HEK293S) cell line was used as standards for the
measurement of mean telomere length. A dilution series (1.56 to
100.00 ng; 2-fold dilution; 7 points) using genomic DNA derived
from the HEK293S cell line were included with each 96-well plate
for the telomere and the b-globin PCRs. The 25-ng standard curve
point was used as the reference sample. The slope of the standard
curve for the telomere and b-globin reactions was 20.22 and
20.35, respectively, and the linear correlation coefficient (R
2)
value for both reactions were .0.99 (File S3). The average inter-
plate coefficient of variability was 6.6% for telomere assays and
4.8% for b-globin assays. As part of routine quality control, 10% of
the samples were randomly chosen to test the reproducibility of the
assay. All measurements were performed by technicians blinded to
the case-control status.
hTERT Gene Variants Selection and Genotyping
Telomere length is regulated by telomerase activity, and the
expression level of human telomerase reverse transcripts (hTERT)
is a major determinant of telomerase activity. The hTERT gene is
located on chromosome 5p15.33 (geneID: 7015), which is strictly
regulated by the transcriptional activity of the promoter region.
We sequenced the promoter region of the hTERT gene (Genbank
accession no. AF098956) [37] in 50 randomly chosed control
subjects and identified three common variants with a minor allele
frequency above 10%, rs2736109 (21600 G/A), rs2735940
(21327T/C), and rs2853669 (2190T/C) with positions defined
by the transcription initiation site as +1 [37] (File S3). By searching
putative nuclear factor-binding sites, we found that rs2853669 is
located at a binding site for the transcriptional factor Ets2, which is
a critical regulator of the hTERT gene expression [37–39]. The
variant rs2735940 (21327T/C) has been reported to be associated
with coronary artery disease in some studies but not replicated in
others [27–29]. Based on the potential biological functions, we
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further analysis in this association study.
The 2 selected variants were genotyped using the polymerase
chain reaction-restriction fragment length polymorphism ap-
proach without knowledge of case or control status (Primers was
shown in File S2). Reproducibility of genotyping was confirmed by
sequencing in 400 randomly selected samples with 100%
concordance.
Construction of hTERT Promoter Plasmids and Luciferase
Reporter Assays
To determine whether the genetic variants and their haplotypes
affect the transcription activity of hTERT gene, a series of
luciferase reporter plasmids were constructed. First, because
rs2853669 resides within a binding site for the transcriptional
factor Ets2 and partly overlapped with the transcriptional factor c-
Myc, which regulates the hTERT gene expression [38], we
generated 2 types of luciferase reporter plasmids containing
rs2853669TT- or CC- genotype: pGL3-rs2853669T and pGL3-
rs2853669C. Second, we generated 4 types of luciferase reporter
plasmids with different haplotypes: pGL3-TT (T-T haplotype with
rs2735940T and rs2853669T), pGL3-TC (T-C haplotype with
rs2735940T and rs2853669C), pGL3-TT (C-T haplotype with
rs2735940C and rs2853669T), and pGL3-CC (C-C haplotype
with rs2735940C and rs2853669C). The 1.5-kb fragment of the
proximal promoter of hTERT gene (Genbank accession
no. AF098956), encompassing rs2735940 and rs2853669, was
amplified and cloned into the pGL3-basic vector (Promega,
Madison, WI, USA). The pGL3-basic vector contains the cDNA
encoding firefly luciferase; when it was fused with a promoter and
transfected into mammalian cells, the construct can be used to
analyze the inserted promoter activity. In addition, we constructed
plasmids for expression of pcDNA3.1-Ets2 and pcDNA3.1-c-Myc,
and investigated whether the transcription factors Ets-2 and c-Myc
modify the effects of genetic variants on the transcription activity
of hTERT gene. Primers for constructing the reporter plasmids
were shown in File S2. All the constructs were confirmed by
sequencing.
Hela cells and Hek293S cells were seeded in 96-well plates,
respectively. On the day of transfection, each well was co-
transfected with 0.2 mg of the pGL3 vector, 5 ng of the pRL-TK
vector (Promega), 0.1 mg of pcDNA3.1-Ets2, or pcDNA3.1-c-Myc
by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
The pRL-TK vector, encoding the Renilla luciferase, was used as
internal control to normalized firefly luciferase expression.
Twenty-four hours after transfection, the cell lysates were
Table 1. Characteristics of peripheral arterial disease patients and control subjects.*
Characteristics Cases with PAD (n=485) Control subjects (n=970) P value
{
Age, years 58.669.4 58.369.4 0.52
Male, n (%) 179 (36.9%) 372 (38.3%) 0.60
Body mass index, kg/m
2 25.263.7 25.763.6 0.07
Waist-hip ratio 0.8760.06 0.8860.06 0.28
Systolic blood pressure, mm Hg 163629 158628 0.002
Diastolic blood pressure, mm Hg 96614 95613 0.10
Glucose, mmol/L 5.6262.19 5.4961.88 0.21
Lipids, mmol/L
Total cholesterol 5.5961.27 5.4661.13 0.05
Triglycerides 1.39 (0.96–1.91) 1.31 (0.95–1.80) 0.28
HDL cholesterol 1.5660.33 1.5560.35 0.35
LDL cholesterol 3.1760.99 3.1060.90 0.15
Serum creatinine, mmol/L 67.9638.0 66.7631.4 0.52
Cigarette smoking, n (%) 105 (21.6%) 178 (18.3%) 0.13
Alcohol intake, n (%) 114 (23.5%) 194 (20.0%) 0.12
Medical history, n (%)
Hypertension 346 (71.3%) 614 (63.2%) 0.002
Diabetes mellitus 21 (4.3%) 35 (3.6%) 0.50
Cardiovascular disease 103 (21.2%) 31 (3.2%) ,0.0001
Medication treatment, n (%)
Antihypertension 294 (85.0%) 507 (82.4%) 0.31
Blood-glucose control, n (%) 18 (85.7%) 25 (69.4%) 0.17
Lipid-lowing therapy 52 (65.8%) 91 (65.5%) 0.96
Telomere length
Relative T/S ratio 1.8861.00 2.7661.51 ,0.0001
PAD indicates peripheral arterial disease; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; T, telomere repeat copy; S, single-copy
gene globin copy.
*Data are given as mean 6 SD, numbers (percentage) or medians (interquartile range). Telomere length is expressed as a relative telomere/single-copy gene (T/S) ratio.
{P value was calculated between PAD patients and control subjects by the two-sample t-test for comparison of continuous variables, the x
2 test for categorical variables,
and the Mann-Whitney U test for triglycerides and telomere length.
doi:10.1371/journal.pone.0047029.t001
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and Firefly and Renilla luciferase activities were measured with a
luminometer (Turner, Sunnyvale, CA, USA). The transfection
efficiency was normalized according to the Renilla luciferase
activity. Each transfection was carried out in triplicate and
repeated 3 times.
Statistical Analysis
Normal distribution of data was examined by the Kolmogorov–
Smirnov normality test. The T/S ratios of mean leukocyte
telomere length were natural logarithm transformed because of a
skewed distribution. Characteristics of cases and controls were
compared by x
2 test for categorical variables and two-sample t test
for quantitative variables. The distributions of the T/S ratio of
telomere length were divided into tertiles among control subjects,
and the cutoff values were ,1.87 for the lowest tertile, 1.87–3.23
for the middle tertile, and .3.23 for the highest tertile. The odds
ratios (ORs) and 95% confidence intervals (CIs) were estimated for
the association between telomeres and the risk of PAD by using
conditional logistic regression models. Multivariate analyses were
adjusted for body mass index, fasting triglycerides, total choles-
terol, high-density lipoprotein cholesterol (HDL-C), fasting blood
glucose, blood pressure, smoking status (never, past, current),
alcohol intake (current drinker, yes/no), and further for medical
history, including hypertension (yes/no), diabetes (yes/no), previ-
ous cardiovascular disease (yes/no), and antihypertensive therapy
(yes/no).
The x
2 test was used to examine the Hardy-Weinberg
equilibrium for each variant and to compare the distribution of
allele and genotype frequencies between cases and control
subjects. Generalized linear regression model was used to compare
the differences in telomere length across the genotypes by
adjustment for the covariates mentioned above. When the overall
difference was statistically significant, a Tukey test was performed
as post hoc test to identify significant differences between the 3
genotype groups. The associations between the hTERT gene
variants and risk of PAD were estimated using conditional logistic
regression analysis by adjustment for the covariates mentioned
above, and the P value was corrected for multiple comparisons (for
the 2 tested variants and the 3 genetic models) by Simes’ method, a
modified Bonferroni procedure [40]. The linkage disequilibrium
between tested variants was calculated using Haploview software
4.2, and the R
2 was used to indicate the strength of linkage
disequilibrium. Haplotype analysis was conducted on the basis of
the Stochastic-EM algorithm using the THESIAS program [41].
The sex-specific associations were also examined by computing the
interaction term.
The population-attributable fraction was estimated for variants
with the following equation: population-attributable frac-
tion%=1006p(OR21)4[p(OR21)+1]; p is the frequency of the
at-risk genotypes among control subjects. All probability values
were 2-sided, and P,0.05 was considered significant. Analyses
were performed with SPSS software, version 13.0 (SPSS Inc,
Chicago, USA).
Results
Clinical Characteristics of Study Participants
In this study, age, presented as mean6SD, was 58.669.4 years
in cases and 58.369.4 years in controls, and men accounted for
36.9% of cases and 38.3% of controls (Table 1). As expected, PAD
patients had a higher prevalence of history of cardiovascular
disease and hypertension; they also had higher levels of systolic
blood pressure and total cholesterol. There were no significant
differences in clinical characteristics by tertiles of mean telomere
length in PAD patients and control subjects, including blood
pressure, smoking, alcohol intake, and medical treatments of
antihypertensive therapy, blood-glucose control and lipid-lowing
therapy (File S2).
Association between Leukocyte Telomere Length and
PAD
The mean leukocyte telomere length was significantly shorter in
PAD patients than in control subjects (mean 6SD: 1.8861.00
versus 2.7661.51; P,0.001; File S3). Overall, the telomere T/S
ratio (natural log-transformed) was significantly inversely correlat-
ed with chronological age, and decreased 8% per decade (95% CI
23.2 to 213.4; correlation coefficient c=20.10; P,0.001) in
control subjects and 6% per decade (95% CI 23.0 to 213.8;
correlation coefficient c=20.11, P,0.001) in PAD patients,
Table 2. Risk of peripheral arterial disease in different tertiles of leukocyte mean telomere length.
In tertile groups of relative T/S ratio
Per 1-SD decrease in
ln-transformed relative
T/S ratio
Highest tertile
(.3.23)
Middle tertile
(1.87–3.23)
Lowest tertile
(,1.87) P for rend P
Cases with PAD (n=485) 49 (10.1%) 147 (30.3% 289 (59.6%)
Control subjects (n=970) 324 (33.4%) 324 (33.5%) 322 (33.2%)
Odds ratio (95%CI)*
Crude model 1.0 1.90 (1.37–2.58) 3.32 (2.47–4.47) ,0.0001 1.78 (1.58–2.01) ,0.0001
Multivariable model I
{ 1.0 1.82 (1.31–2.55) 3.22 (2.36–4.38) ,0.0001 1.77 (1.57–1.99) ,0.0001
Multivariable model II
{ 1.0 1.71 (1.24–2.36) 3.12 (2.32–4.18) ,0.0001 1.75 (1.55–1.97) ,0.0001
Multivariable model III1 1.0 1.73 (1.29–2.49) 3.15 (2.31–4.29) ,0.0001 1.74 (1.54–1.97) ,0.0001
PAD indicates peripheral arterial disease; CI, confidence interval.
*Odds ratio and 95%CI were obtained with multivariate conditional logistic regression analysis.
{Model I: Adjustment for body mass index, systolic and diastolic blood pressure, smoking, alcohol intake, fasting glucose, triglycerides, total cholesterol, HDL cholesterol,
and LDL cholesterol.
{Model II: Adjustment for the covariates mentioned above plus diabetes, history of hypertension, previous cardiovascular disease, and medication treatment.
1Model III: Adjustment for individual genetic variants rs2735940 and rs2853669 of the hTERT gene, except for the covariates mentioned in Model II.
doi:10.1371/journal.pone.0047029.t002
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regression line slopes between controls and cases (P=0.42).
In both crude analysis and multivariable analysis adjustment for
conventional vascular risk factors, individuals in the lowest and
middle tertiles of telomere length had a significantly higher risk of
PAD than did those in the highest tertile (multivariate OR 1.71,
95%CI 1.24–2.36 in the middle tertile; 3.12, 95%CI 2.32–4.18 in
the lowest tertile; P for trend,0.0001); and further adjustment for
the effect of genetic variants in the hTERT gene, the association
between shorter telomere lengths and increased risk of PAD was
not remarkably changed (Table 2). The associations were not
observed a sex-specific effect. In subsidiary analyses, telomere
length was analyzed as a continuous variable and was associated
with 75% increased risk of developing PAD per 1-SD decrease
(multivariate OR 1.75, 95%CI 1.55–1.97; P,0.0001). We also
tested for the effect modification by age, gender, smoking, alcohol
intake, history of hypertension, medication treatment, and genetic
variants by performing analyses stratified by these variables and by
evaluating interaction terms. Decrease of leukocyte telomere
length remained to be associated with the risk of PAD in various
groups (File S3). Because the observed association between shorter
telomeres and PAD could be biased due to the association with
coronary heart disease, we also performed sensitivity analyses by
excluding those subjects with history of heart diseases, and the
results were not substantially changed (File S2). Of the risk factors
measured, marginally significant inverse associations were found
between telomere length and waist-hip ratio, serum total
cholesterol, and LDL cholesterol, which indicated that longer
telomeres corresponded with a better health status (File S2).
hTERT Gene Variants Predispose to Telomere Length
Shortening and PAD Risk
The frequencies of rs2735940 and rs2853669 in the hTERT
gene did not deviate significantly from Hardy-Weinberg equilib-
rium in this case-control sample population (all P.0.05). Before
implementation of this study, we performed a statistical power
analysis to verify whether the recruited sample could provide
adequate power to identify the genetic association [42]. Based on
the present sample size, assuming 80% statistical power, at an
alpha of 0.05, we had the ability to detect an association with ORs
of $1.10 if the minor allele frequency is 0.50 and $1.90 if the
minor allele frequency is 0.01, assuming an additive model.
In an allelic association analysis, the presence of the C-allele of
rs2853669 was associated with increased risk of PAD (Table 3).
Table 3. Association between variants in the TERT gene and risk of peripheral arterial disease.
Genetic variants
PAD cases
(n=485)
Controls
(n=970)
Crude OR
(95%CI)*
Adjusted OR
(95%CI)
{ Adjusted P
{ Corrected P
{
rs2735940 (21327T.C)
Allele
T 57.6% 60.1%
C 42.4% 39.9%
Allelic Association 1.11 (0.95–1.30) 1.08 (0.90–1.26) 0.21 0.56
Genotype, n (%)
TT 160 (33.0%) 322 (33.3%) Ref. Ref.
TC 239 (49.3%) 522 (53.8%) 0.92 (0.72–1.18) 0.87 (0.68–1.12) 0.29 0.58
CC 86 (17.7%) 126 (13.0%) 1.38 (0.99–1.92) 1.27 (0.90–1.79) 0.17 0.51
Additive model (CC vs.TC vs.TT) 1.12 (0.95–1.32) 1.08 (0.91–1.28) 0.37 0.74
Dominant model (CC+TC vs.TT) 1.01 (0.80–1.28) 0.97 (0.76–1.23) 0.78 0.78
Recessive model (CC vs. TC+TT) 1.44 (1.06–1.94) 1.38 (1.01–1.88) 0.04 0.24
rs2853669 (2190T.C)
Allele
T 56.7% 62.5%
C 43.3% 37.5%
Allelic Association 1.27 (1.09–1.49) 1.21 (1.02–1.40) 0.002 0.02
Genotype, n (%)
TT 149 (30.7%) 367 (37.8%) Ref. Ref.
TC 252 (52.0%) 478 (49.3%) 1.30 (1.02–1.65) 1.27 (0.99–1.64) 0.06 0.36
CC 84 (17.3%) 125 (12.9%) 1.66 (1.18–2.32) 1.62 (1.14–2.29) 0.006 0.05
Additive model (CC vs.TC vs.TT) 1.29 (1.10–1.52) 1.27 (1.08–1.51) 0.005 0.04
Dominant model (CC+TC vs.TT) 1.37 (1.09–1.73) 1.35 (1.06–1.71) 0.005 0.04
Recessive model (CC vs. TC+TT) 1.42 (1.03–1.90) 1.38 (1.01–1.89) 0.04 0.16
PAD indicates peripheral arterial disease; OR, odds ratio.
*Crude ORs (95%CI) were determined by x
2 test, cases vs. control subjects.
{Adjusted ORs (95%CI) and adjusted P value were obtained with multivariate conditional logistic regression analysis by adjusting for body mass index, triglycerides, total
cholesterol, HDL cholesterol, LDL cholesterol, blood glucose, blood pressure, smoking, alcohol intake, diabetes, history of hypertension and cardiovascular disease,
medication treatment, and telomere lengths.
{Corrected P value was obtained by the Simes’ procedure, a modified Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0047029.t003
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PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e47029Figure 1. Correlations between telomere length and hTERT gene variants. Data shown were the means 6 S.E.M. S.E.M. denotes standard
error of the mean. Multiple linear regression analysis was used to compare the mean leukocyte telomere lengths by genotypes of rs2853669 (Panel A)
or by haplotypes containing rs2735940 and rs2853669 (Panel B) in the hTERT gene promoter region among PAD patients and control subjects,
respectively, after adjustment for age, gender, and conventional vascular risk factors. Haplotype analysis was conducted on the basis of the
Stochastic-EM algorithm using THESIAS program, and possesses 2 loci rs2735940 and rs2853669 from left to right. **P=0.005, compared with wild-
type TT genotype; P=0.002 and P=0.08, compared with wild-type T-T haplotype.
doi:10.1371/journal.pone.0047029.g001
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telomere lengths, subjects with the CC genotype of rs2853669 had
higher susceptibility to PAD compared with the wild-type TT
genotype carriers (additive model: OR 1.27, 95%CI 1.08–1.51,
P=0.005; dominant model: OR 1.35, 95%CI 1.06–1.71,
P=0.005; Table 3). The estimated population-attributable frac-
tion for PAD was 8.9% for the at-risk genotype of CC. After
correction for multiple testing by Simes’ procedure, the associa-
tions remained statistically significant. Because hypertension is an
important risk factor for PAD, an additional analysis in the
hypertensive patients was conducted, and our data showed that
these positive associations were independent of the status of
hypertension. For the variant rs2735940, we did not observe the
association with PAD after adjustment for vascular risk factors and
further for multiple testing.
Figure 1A showed the mean leukocyte telomere length by
genotypes of rs2853669 in the hTERT gene. After adjustment for
age, gender, and other vascular risk factors with multiple linear
regression analysis, telomere length was correlated to rs2853669 in
PAD patients, but not the controls, and the standardized
coefficient b for the at-risk C-allele of rs2853669 was 20.17
(P=0.005) compared to the wild-type T-allele. The mean
leukocyte telomere length was markedly shorter in carriers with
the CC genotype of rs2853669 than that in the TT carriers among
PAD patients (1.6060.11 vs. 2.0360.08; P=0.005; Figure 1A). No
correlations were found between telomere length and the variant
rs2735940 (File S2).
In addition, given that the effect of a single gene or variant on a
complex disease is expected to be modest, a haplotype analysis
using the 2 variants (rs2735940 and rs2853669) was performed to
assess the haplotype effect on telomere length shortening and the
risk of PAD. Subjects with the at-risk C-C haplotype had shorter
telomere length than those individuals with the wild-type T-T
haplotype among PAD patients (1.0460.09 vs. 1.9760.12;
P=0.002), while a marginally significant difference was found
among the controls (Figure 1B). Consistently, the C-C haplotype
was associated with 1.30-fold (OR 1.30, 95%CI 1.06–1.58;
P=0.005) increased risk of PAD after adjustment for vascular
risk factors and telomere lengths (Table 4).
hTERT promoter with C-C haplotype had lower
transcription activity
To investigate whether the individual variants and haplotypes
affect the transcription activity of hTERT gene, we constructed a
series of luciferase reporter plasmids containing rs2735940 and
rs2853669 and measured the luciferase activity representative of
hTERT promoter activity. The results showed that the
rs2863669CC genotype has 17% decreased luciferase activity
than the wild-type genotype of rs2863669TT (P=0.02, Figure 2).
When co-transfected with the transcriptional factors Ets2 and c-
Myc in in vivo luciferase assays, Ets2 and c-Myc had a combined
effect by enhancing the promoter activity of hTERT gene, and the
promoter activity of the rs2863669CC genotype decreased 22%
(Figure 2).
Compared with the wild-type T-T haplotype, the hTERT
promoter haplotype carrying the at-risk rs2853669C allele had
significantly lower luciferase activity, with 31% decrease for the T-
C haplotype and 43% decrease for the C-C haplotype (P,0.001),
respectively; whereas no significant difference was detected for the
C-T haplotype with no stimuli of transcriptional factors (Figure 3).
When co-transfected with the transcriptional factors Ets2 and c-
Myc in in vivo luciferase assays, a combined effect on the promoter
activity of hTERT gene was observed, and the transcription
activity of the C-T, T-C or C-C haplotypes decreased significantly
compared with the wild-type T-T haplotype (Figure 3). Results in
Hela cells were consistent with that in Hek293S cells (data not
shown).
Discussion
In the present study, to our knowledge, our data for the first
time showed that leukocyte telomere length shortening is
significantly associated with increased risk for atherosclerotic
PAD. We also found that a loss-of-function haplotype C-C
(rs2735940 and rs2853669) in the promoter region of the hTERT
gene (a major determinant of telomerase activity), affects the
transcriptional power in vivo luciferase activity assays and is
associated with shorter telomere length in patients with athero-
sclerotic PAD. In addition, our results showed that carriers with
the at-risk C-C haplotype have increased risk for the development
of PAD. The associations were independent of those conventional
vascular risk factors.
Atherosclerotic PAD, a common manifestation of systematic
atherosclerosis, is closely linked to the aging of human beings.
Although classic risk factors, such as smoking, diabetes mellitus,
hyperlipidemia, and hypertension, have been found to predict the
occurrence of PAD, there is wide variation in disease manifestation
in individuals who have the similar risk profile. Telomere length
serves as a potential marker of human aging because of its
important features as ‘biological clock’ in genome stability; for
example, it decreases progressively with chronological age, varies
Table 4. Haplotype analysis of variants rs2735940 and rs2853669 and the risk of peripheral arterial disease.
Controls Cases Crude ORs Multivariable model I
{ Multivariable model II
{
Haplotypes* (n=970) (n=485) (95% CI) ORs (95% CI) P ORs (95% CI) P
T-T 0.477 0.446 Ref. Ref. Ref.
T-C 0.124 0.130 1.08 (0.83–1.39) 1.10 (0.84–1.43) 0.49 1.06 (0.80–1.34) 0.43
C-T 0.148 0.122 0.84 (0.65–1.09) 0.84 (0.64–1.10) 0.20 0.82 (0.62–1.05) 0.18
C-C 0.251 0.302 1.33 (1.09–1.61) 1.36 (1.12–1.66) 0.002 1.30 (1.06–1.58) 0.005
Global P 0.003 0.004
*Haplotype analysis was conducted on the basis of the Stochastic-EM algorithm using THESIAS program. Haplotypes possess 2 loci rs2735940 and rs2853669 from left
to right.
{Multivariable model I: Adjustment for conventional risk factors, including body mass index, triglycerides, total cholesterol, HDL cholesterol, blood glucose, blood
pressure, smoking, alcohol intake, diabetes, history of hypertension, and medication treatment.
{Multivariable model II: Adjustment for telomere lengths, except for those covariates mentioned in model I.
doi:10.1371/journal.pone.0047029.t004
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linked to inflammation and oxidative stress.
We observed a linear correlation between telomere shortening
and chronological age in the current study, and on average the
leukocyte telomere length in our PAD patients was comparable to
that of control subjects chronologically 5 years older. Our findings
lend support to the hypothesis that premature biological aging
may contribute to the risk of PAD. Although the exact mechanism
explaining the relationship between shorter telomere length and
PAD cannot be determined from our study alone, there are several
plausible explanations. Decreased telomere length in circulating
leukocytes mirrors the replicative history of bone marrow-derived
endothelial progenitor cells which have been considered as
important agents of vascular repair [43]. Telomere shortening-
induced endothelial cell senescence has also been reported in
human atherosclerotic plaque lesions [11]. In addition to the
effects on vascular repair and endothelial progenitor cell function,
telomere shortening can increase the level of circulating pro-
inflammatory cytokines and oxidative burden, which are central to
the pathogenesis of atherosclerosis and arterial stiffness. Indeed,
epidemiological studies have shown that telomere length shorten-
ing may be used as a potential marker for age-related diseases [44],
most notably coronary heart disease [31,32].
Of the telomerase-associated pathway genes that encode
proteins for the telomere-specific nucleoprotein complex, telome-
rase reverse transcriptase (hTERT) is the rate-limiting catalytic
subunit and a major determinant of telomerase activity [45].
hTERT expression is strictly regulated at the transcription
Figure 2. Effect of individual variant rs2853669 on the promoter transcription activity of hTERT gene. The luciferase reporter plasmids
containing the hTERT gene promoter region with rs2853669TT- or CC- genotype were constructed and then transfected into Hek293S cells. The pGL3-
Basic is the promoter-less vector as a negative control. Firefly luciferase activity was expressed relative to control, normalized to Renilla luciferase
activity to correct for transfection efficiency. (A) Without co-transfection of transcription factors Ets2 and c-Myc; (B) With co-transfection of Ets2; (C)
With co-transfection of c-Myc; (D) With co-transfection of both Ets2 and c-Myc. Data shown are the means 6 SD, n=3. *P=0.02, P=0.03, **P,0.001,
compared with the relative luciferase activity of the wild-type rs2853669T.
doi:10.1371/journal.pone.0047029.g002
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in the hTERT promoter region interfere with the activation/
depression of hTERT gene and are associated with the inter-
individual variation of telomere length. In the present study, we
found that a loss-of-function haplotype C-C (rs2735940 and
rs2853669) within the promoter region of the hTERT gene is
associated with shorter telomere length and increased risk for the
development of atherosclerotic PAD. The biological relevance of
these observations is further supported by our results in vivo
luciferase activity assays which showed a lower transcription power
for the C-C haplotype.
Genetic variant rs2853669 is located at 190 bp upstream the
hTERT transcription starting site, residing within a specific binding
site for Ets2, which has been suggested to be a positive regulator of
the hTERT gene and to be required for telomerase activation [38].
A transition from T to C of rs2853669 results in the damage of
Ets2 core binding sequence ‘GGAA/T’, which may affect the
binding ability of Ets2 and therefore the transcriptional efficiency
and expression level of the hTERT gene. Consistent with our
study, a decreased telomerase activity has been related to the
rs2853669C allele in a recent study on non-small cell lung cancer
[38]. In addition, the sequence containing rs2853669T/C also
partly overlapped with the binding site of transcriptional factor c-
Myc which plays a critical role in the hTERT gene expression
[37,38]. It is reasonable to speculate that an interaction
mechanism exists, which determines the Ets-Myc overall effect
at this described polymorphism site. Our experiments in vivo
luciferase assays further showed that transcription power of the
hTERT gene was significantly enhanced with the co-expression of
Ets2 and c-Myc compared with the presence of either Ets2 or c-
Myc. Recent evidence also supports that Ets2 transcription factor
probably play as a positive regulator of hTERT gene, especially
when c-Myc proteins are also expressed [39]. The other variant
rs2735940T/C is located at 1327 bp upstream the hTERT
transcription starting site and its relations with telomere shortening
and coronary artery disease are not consistent in various studies
[27–29]. Although our data did not observe the single-locus
association between rs2735940 and telomere length or athero-
sclerotic PAD, haplotype analysis showed that subjects carrying
both rs2735940C and rs2853669C have shorter telomere length
Figure 3. Haplotype effect of variants rs2735940 and rs2853669 on the promoter transcription activity of hTERT gene. The luciferase
reporter plasmids containing the hTERT gene promoter region with haplotype T-T, T-C, C-T, or C-C (rs2735940 and rs2853669) were constructed and
then transfected into Hek293S cells. (A) Without co-transfection of transcription factors Ets2 and c-Myc; (B) With co-transfection of Ets2; (C) With co-
transfection of c-Myc; (D) With co-transfection of both Ets2 and c-Myc. Data shown are the means 6 SD, n=3. **P,0.001, compared with the relative
luciferase activity of the wild-type haplotype T-T.
doi:10.1371/journal.pone.0047029.g003
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with the wild-type haplotype.
Several limitations should be considered. First, not all variants
at the hTERT gene were assessed in this study, complete
sequencing will be necessary for systematic identification of
potentially causative mutations. Second, leukocyte telomere
lengths were measured from the DNA from patients after
diagnosis of PAD in the present study, which in turn could have
already been affected by disease progression; therefore, more
prospective studies in various populations are needed. Third,
technical challenges further complicate the measurement of
telomere length. While the quantitative PCR-based assay is the
most economical, high-throughput method for telomere length
measurements in large epidemiologic studies [31,32,36], values are
relative representations of the average telomere length. However,
the PCR-based method has been previously shown to be highly
consistent with classic Southern blotting [31,32], which suggests
that assessment of mean telomere length using the PCR-based
method is reliable. The range of T/S ratio in the present study is
relatively high than other publications using the similar quantita-
tive PCR method. Most publications used one studied sample as
the calibrator sample of telomere length measurement [2], and
thus commonly available standards were lack. Here, the present
study used the human embryonic kidney 293 cell line as standard,
which represent a well-characterized standard to gain comparable
measures between studies [46]. More replication studies are
further needed.
A number of suggestive genetic loci for telomere length in
humans have been identified through family-based linkage studies
[19–21] and genome-wide association analyses [22–26]. Although
the genome-wide association studies have been spectacularly
successful so far in complex traits, such as myocardial infarction
and diabetic mellitus, it is an open question whether we will
ultimately be able to identify most of the genetic variation that
accounts for common diseases using this approach. For example,
only the TERC locus, encoding the RNA template component of
telomerase, has been identified and replicated in multiple
independent populations for its association with telomere length
[23–25,47]; however, it accounts for no more than 1% of variation
in telomere length [24], and no associations with atherosclerotic
vascular diseases were observed [27].
Conclusions
Aging is a major risk factor for atherosclerotic PAD. Our study
showed that shorter leukocyte telomere length is significantly
associated with increased risk for the development of PAD,
independent of those conventional vascular risk factors. Subjects
with the at-risk C-C haplotype (rs2735940 and rs2853669) of the
hTERT gene (a major determinant of telomerase activity), have
shorter telomere length and a higher prevalence of PAD. These
results are further supported by functional analysis that the C-C
haplotype affects the transcriptional ability of the hTERT gene.
These observations support the hypothesis that telomere shorten-
ing can be used as a prognostic marker for age-related
atherosclerotic PAD. Nevertheless, further studies in larger
samples are needed to support our intriguing finding.
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